ImmuneRegen BioSciences, Inc. (IRBO) Invited to Submit Full Proposal to Biomedical Advanced Research and Development Authority (BARDA) for Homspera(R) as a Potential Medical Countermeasure for Injury Associated With Radiation Exposure  
8/31/2010 1:37:37 PM

SCOTTSDALE, Ariz., Aug. 31, 2010 (GLOBE NEWSWIRE) -- ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB:IRBS), today announced that after review of the company's proposal outline submitted in late 2009 advocating the development of Homspera as a medical countermeasure against radiation-induced injury, the Biomedical Advanced Research and Development Authority (BARDA) has invited ImmuneRegen to submit a full proposal for a multi-year, multi-million dollar contract to develop Homspera towards FDA approval. BARDA supports the development of diagnostics and therapeutics to counter Chemical, Biological, Radiological and Nuclear (CBRN) threats as well as Pandemic Influenza/Emerging Infections to the United States.